We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Burford Capital
BUR
$918M
| $12.2M | 0.03% |
1,003,361
| – | – |
|
502
HDFC Bank
HDB
$116B
| $12.1M | 0.03% |
346,668
+29,528
| +9% | +$996K |
|
503
The RMR Group
RMR
$327M
| $12M | 0.03% |
517,832
-11,157
| -2% | -$261K |
|
504
ICICI Bank
IBN
$102B
| $11.8M | 0.03% |
512,093
-139,874
| -21% | -$3.16M |
|
|
AVDX
505
DELISTED
AvidXchange
AVDX
| $11.8M | 0.03% |
1,137,619
+310,897
| +38% | +$2.8M |
|
506
Coca-Cola Consolidated
COKE
$13.2B
| $11.8M | 0.03% |
185,160
-25,360
| -12% | -$1.57M |
|
507
Fate Therapeutics
FATE
$282M
| $11.8M | 0.03% |
2,469,299
+806,978
| +49% | +$4.45M |
|
508
RLI Corp
RLI
$5.63B
| $11.7M | 0.03% |
171,914
+94,036
| +121% | +$6.25M |
|
509
Columbia Sportswear
COLM
$2.89B
| $11.7M | 0.03% |
151,507
-59,791
| -28% | -$4.82M |
|
510
Procore
PCOR
$7.99B
| $11.7M | 0.03% |
179,548
+128,837
| +254% | +$7.58M |
|
|
CFLT
511
DELISTED
Confluent
CFLT
| $11.6M | 0.03% |
329,543
+228,222
| +225% | +$6.39M |
|
512
Estee Lauder
EL
$34.8B
| $11.6M | 0.03% |
59,248
-62,117
| -51% | -$13.2M |
|
513
Waste Management
WM
$86.8B
| $11.6M | 0.03% |
66,952
-28,622
| -30% | -$4.73M |
|
|
VRTV
514
DELISTED
VERITIV CORPORATION
VRTV
| $11.6M | 0.03% |
92,424
-1,517
| -2% | -$177K |
|
515
MaxLinear
MXL
$6.09B
| $11.6M | 0.03% |
366,248
+9,246
| +3% | +$267K |
|
516
Workiva
WK
$4.07B
| $11.5M | 0.03% |
112,669
-292
| -0.3% | -$28.1K |
|
517
Service Corp International
SCI
$11.1B
| $11.4M | 0.03% |
177,017
-117,044
| -40% | -$7.82M |
|
518
Nu Holdings
NU
$68.5B
| $11.2M | 0.03% |
+1,419,914
| New | +$8.72M |
|
|
SWAV
519
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $11.2M | 0.03% |
39,215
+33,555
| +593% | +$9.32M |
|
520
Genuine Parts
GPC
$18.1B
| $11.1M | 0.03% |
65,755
+49,235
| +298% | +$8.06M |
|
521
Fortis
FTS
$27.3B
| $11.1M | 0.03% |
256,976
+15,117
| +6% | +$659K |
|
522
Lazard
LAZ
$3.76B
| $11M | 0.03% |
345,144
-17,117
| -5% | -$529K |
|
523
Keysight
KEYS
$53.3B
| $11M | 0.03% |
65,849
-3,950
| -6% | -$613K |
|
524
Outset Medical
OM
$59M
| $10.9M | 0.03% |
33,367
+15,767
| +90% | +$4.81M |
|
525
3M
MMM
$84.9B
| $10.9M | 0.03% |
130,643
+124,626
| +2,071% | +$10.6M |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.